MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (18) , 5445-53
Abstract
The current standard treatment option for advanced hepatocellular carcinoma (HCC) is sorafenib, but its clinical benefit is modest. In spite of many attempts, few drugs can provide any significant improvement of survival as the first- or second-line therapy of choice in phase III randomized controlled trials. Recently, the subgroup analysis of a phase II randomized controlled trial has shown that tivantinib, a selective MET inhibitor, can significantly improve the overall survival in patients with MET-positive advanced HCC after the failure or intolerance of a prior systemic therapy. These findings enlighten the role of MET inhibitors in the treatment of advanced HCC. In this paper, we review all ongoing and completed clinical trials regarding this topic. As for the first-line therapy of advanced HCC, INC280 and foretinib are being evaluated in 2 phase II single-arm trials; and MSC2156119J and golvatinib plus sorafenib are being compared with sorafenib alone in 2 phase II randomized controlled trials. As for the second-line therapy of advanced HCC, tivantinib and cabozantinib are being compared with placebo in 2 phase III randomized controlled trials.Keywords
This publication has 47 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerJournal of Clinical Oncology, 2011
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in CancerClinical Cancer Research, 2009
- Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma #Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotypeJournal of Clinical Investigation, 2006
- Expression of Hepatocyte Growth Factor and Its Receptor, the C– Met Proto–Oncogene, in Hepatocellular CarcinomaHepatology, 1997